Sotorasib is a inhibitor that recently received approval for use in locally advanced or metastatic -mutated NSCLC. CodeBreaK100, the phase 2 clinical trial leading to the approval of sotorasib, excluded patients with untreated brain metastases; there have been no reports describing efficacy of sotorasib on untreated brain metastases. We present a case of a patient with active untreated brain metastases with resulting disorientation and weakness who has radiographic response and complete resolution of neurologic symptoms with sotorasib. Our case illustrates the intracranial activity of sotorasib, but additional studies are needed to characterize the intracranial response rate and duration of response in these patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719091 | PMC |
| http://dx.doi.org/10.1016/j.jtocrr.2022.100428 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Aneurysm dome and vessel pressure measurements with coiling, stent assisted coiling and flow diversion.
Acta Neurochir (Wien)
January 2025
Division of Neurosurgery, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street , Boston, MA, 02215, USA.
Background: Variability in long-term endovascular treatment outcomes for intracranial aneurysms has prompted questions regarding the effects of these treatments on aneurysm hemodynamics. Endovascular techniques disrupt aneurysmal blood flow and shear, but their influence on intra-aneurysmal pressure remains unclear. A better understanding of aneurysm pressure effects may aid in predicting outcomes and guiding treatment decisions.
View Article and Find Full Text PDFPlasma Biomarkers, Hippocampal Volume and Cognitive Effects of Oral ALZ‐801: The Phase 2 Biomarker Study and its Long‐Term Extension in APOE4 Carriers with Early Alzheimer’s Disease.
Alzheimers Dement
December 2024
Alzheon, Inc., Framingham, MA, USA
Background: ALZ‐801 (valiltramiprosate) is an oral inhibitor of amyloid oligomer formation in development as a disease‐modifying AD treatment, including a fully enrolled APOLLOE4 Phase 3 trial in 325 APOE4/4 homozygotes. A Phase 2 study is evaluating ALZ‐801 effects on plasma biomarkers, brain volumes and cognitive outcomes in APOE4 carriers. Plasma p‐tau reduction over 104 weeks is primary endpoint.
View Article and Find Full Text PDFDeferoxamine treatment decreases amyloid fibrils and lowers iron mediated oxidative damage in ApoEFAD mice.
Alzheimers Dement
December 2024
USC Leonard Davis School of Gerontology, Los Angeles, CA, USA
Background: Iron is implicated in Alzheimer’s disease (AD) and is bound to β‐amyloid (Ab) plaques. AD brains have increased 4‐hydroxynonenal (HNE) adducts, a lipid decomposition product bound to proteins originating from iron mediated lipid peroxidation. Increased brain iron may result from cerebral microbleeds which by nature are rich sources of iron.
View Article and Find Full Text PDFTranscranial electric field stimulation on iron deposition cures multiple pathologies of Aß, tau, microglial inflammation and improves cognitive impairment in Alzheimer’s mouse model.
Alzheimers Dement
December 2024
Daegu Catholic University, Daegu, Daegu Metropolitan City, Korea, Republic of (South)
Background: The interplaying neuropathology of amyloid plaque, tau tangles, and microglia‐driven inflammation (tri‐pathology) are related to neuronal and synaptic loss damage in Alzheimer’s damages. Interventions that target Aβ or tau individually have not yielded substantial breakthroughs. Iron plays a pivotal role in tri‐pathology by protein‐bound iron‐oxide deposition in amyloid plaque, tau tangle, and microglia, resulting in redox‐active toxicity or microglial response induction, such as proinflammatory activation, autophagy dysfunction, and ferroptosis.
View Article and Find Full Text PDFTarget Engagement and Therapeutic Effects of AR1001, a Phosphodiesterase‐5 Inhibitor, in Alzheimer’s Disease Models.
Alzheimers Dement
December 2024
AriBio Co., Ltd., Seongnam, Korea, Republic of (South)
Background: AR1001 is a specific inhibitor of phosphodiesterase‐5 (PDE5), which degrades cyclic guanosine monophosphate (cGMP). cGMP/cAMP response element‐binding protein (CREB)/brain‐derived neurotrophic factor (BDNF) signaling, which is critical for learning and memory processes, is disturbed in Alzheimer’s disease (AD). AR1001 at the oral dose of 30 mg QD is currently in a global Phase 3 clinical trial in early AD patients (NCT05531526).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!